Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 6, 2011

Primary Completion Date

December 28, 2016

Study Completion Date

December 28, 2016

Conditions
Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell Lymphoma
Interventions
DRUG

prednisone

Given PO

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given PO or IV

DRUG

Vincristine

Given IV

DRUG

pralatrexate

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

comparative genomic hybridization

Correlative studies

GENETIC

gene expression analysis

Correlative studies

GENETIC

nucleic acid sequencing

Correlative studies

GENETIC

mutation analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

microarray analysis

Correlative studies

GENETIC

RNA analysis

Correlative studies

Trial Locations (9)

27710

Duke University Medical Center, Durham

30308

Emory University School Of Medicine, Atlanta

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

63110

Siteman Cancer Center, Washington University, St Louis

85259

Mayo Clinic, Arizona, Scottsdale

94305

Stanford University, Stanford

01655

University of Massachusetts Medical School, Worcester

68198-6805

Eppley Cancer Center, University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

University of Nebraska

OTHER

NCT01336933 - Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter